Effect of biologic treatments on growth in children with juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 41, Issue 1, 2014, Pages 128-135

  Uettwiller, Florence ^a   Perlbarg, Julie ^b   Pinto, Graziella ^b   Bader Meunier, Brigitte ^b   Mouy, Richard ^b   Compeyrot Lacassagne, Sandrine ^b   Melki, Isabelle ^b   Wouters, Carine ^c   Prieur, Anne Marie ^b   Landais, Paul ^b   Polak, Michel ^b   Quartier, Pierre ^b  

^a UNIVERSITÉ DE TOURS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c University Hospital Gasthuisberg   (France)

Author keywords

Biologic treatment; Cytokine; Growth; Juvenile arthritis; Systemic juvenile arthritis

Indexed keywords

ADALIMUMAB; CANAKINUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BIOLOGICAL THERAPY; BODY HEIGHT; CHILD; CHILD GROWTH; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG INDICATION; DRUG USE; FEMALE; FOLLOW UP; GROWTH RATE; GROWTH RETARDATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PUBERTY; RETROSPECTIVE STUDY; STEROID THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

BIOLOGIC TREATMENT; CYTOKINE; GROWTH; JUVENILE ARTHRITIS; SYSTEMIC JUVENILE ARTHRITIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; TREATMENT OUTCOME;

EID: 84891781012     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130311     Document Type: Article

References (35)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
3. Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:393-9.
4. Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N, et al. Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 1997;26:99-103.
5. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009;72 Suppl 1:20-5.
6. Chedeville G, Quartier P, Miranda M, Brauner R, Prieur AM. Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine 2005;72:392-6.
7. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Linear growth in children suffering from juvenile idiopathic arthritis requiring steroid therapy: natural history and effects of growth hormone treatment on linear growth. J Pediatr Endocrinol Metab 2001;14 Suppl 6:1483-6.
8. Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007;92:2567-73.
9. Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, et al. Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 2007;92:3013-8.
10. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
11. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48:1093-101.
12. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
13. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22.
14. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802.
15. Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology 2010;49:1550-8.
16. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3259-64.
17. Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 2003;21:779-84.
18. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002;29:1296-300.
19. Landais P, Messiaen C, Rath A, Le Mignot L, Dufour E, Ben Said M, et al. CEMARA an information system for rare diseases. Stud Health Technol Inform 2010;160:481-5.
20. Tanner JM. Growth at adolescence; with a general consideration of the effects of hereditary and environmental factors upon growth and maturation from birth to maturity. 2nd ed. Oxford: Blackwell Scientific Publications; 1962.
21. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006;33:789-95.
22. Sempé M, Pédron G, Roy-Pernot MP, eds. Auxologie méthode et séquences. Paris: Théraplix; 1979.
23. Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child 1970;45:755-62.
24. Karlberg J, Fryer JG. A method for adjustment of final height for midparental height for Swedish children. Acta Paediatr Scand 1990;79:468-9.
25. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
26. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557-67.
27. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
28. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
29. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
30. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
31. Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007;34:2481-5.
32. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006;65:1044-9.
33. Souza LS, Machado SH, Brenol CV, Brenol JC, Xavier RM. Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis. J Rheumatol 2008;35:2265-71.
34. De Benedetti F, Martini A. Cytokines et de retard de croissance au cours des maladies inflammatoires chroniques chez les enfants (French). Cytokines and growth delay during chronic inflammatory diseases in children. Arch Pediatr 1999;6:499-502.
35. Czernichow P. Growth and development abnormalities in children with juvenile idiopathic arthritis: treatment and prevention. Horm Res 2009;72 Suppl 1:1-3.